3 Companies Redefining Healthcare Innovation
This article was originally published on ETFTrends.com. The Healthcare Technology and Innovation index (HTEC) was launched back in…
What’s the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.
Investors are always on the lookout for the next revolutionary technology or product. In recent times, this has…
Harmful cholesterol levels cut in half with one-time gene editing drug in early trial
Altering a single gene may help people lower dangerously high levels of cholesterol and other fats in the…
After 1- and 6-Month Gains, Gene Editing Companies Await Q3 Results
As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in…
CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform
CRISPR Therapeutics AG -Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a…
Here Are 2 With Even More Upside Ahead
On Sept. 30, Pfizer announced a deal with the U.S. government that will allow the pharmaceutical leader to…